The clustering of Cardiovascular, Renal, Adipo-Metabolic Eye and Liver disease with type 2 diabetes

被引:18
|
作者
Thomas, M. C. [1 ]
机构
[1] Monash Univ, Dept Diabet, Melbourne, Vic, Australia
来源
METABOLISM-CLINICAL AND EXPERIMENTAL | 2022年 / 128卷
关键词
Diabetic complications; Type; 2; diabetes; Cardiovascular disease; Diabetic foot disease; Diabetic eye disease; Metabolic-associated fatty liver disease; Diabetic kidney disease; CHRONIC KIDNEY-DISEASE; RISK-FACTORS; HEART-FAILURE; SICK FAT; MELLITUS; MORTALITY; METAANALYSIS; PREVALENCE; ALBUMINURIA; OUTCOMES;
D O I
10.1016/j.metabol.2021.154961
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes is associated with an increased risk of cardiovascular disease, heart failure, chronic kidney disease, fatty liver disease, eye and foot disease. But equally, these conditions are associated with an increased risk of type 2 diabetes. Rather than being simply considered complications of diabetes, as exists within a 'pure' type 1 diabetes paradigm, both type 2 diabetes and its comorbidities are primarily caused by a failure to effi-ciently sequester excess energy leading to the accumulation of sick fat (adiposopathy). Type 2 diabetes is a symptom of a chronic disease complex, just as cardiovascular, renal, eye, foot and/or liver disease, are. In addition, each of these conditions feed forward so that dysfunction in one system accelerates dysfunction in another, partly through their shared pathogenesis and partly due dysfunction that follows in their wake. This review will explore the sticky, brittle conglomeration of CArdiac, Renal, Adipo-Metabolic, Eye and Liver disease (hereafter collectively known as CARAMEL disease) that is coincident in most patients with type 2 diabetes and contextualise the recent changes in diabetes guidelines that now specifically focus on identifying and aggressively managing these high-risk individuals with it. (c) 2021 Published by Elsevier Inc.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus
    Cherney, David Z., I
    Repetto, Enrico
    Wheeler, David C.
    Arnold, Suzanne, V
    MacLachlan, Sharon
    Hunt, Philip R.
    Chen, Hungta
    Vora, Jiten
    Kosiborod, Mikhail
    AMERICAN JOURNAL OF NEPHROLOGY, 2020, 51 (01) : 74 - 82
  • [2] Progression of cardiovascular autonomic neuropathy and cardiovascular disease in type 2 diabetes
    Yun, Jae-Seung
    Park, Yong-Moon
    Cha, Seon-Ah
    Ahn, Yu-Bae
    Ko, Seung-Hyun
    CARDIOVASCULAR DIABETOLOGY, 2018, 17
  • [3] Polygenic risk for type 2 diabetes, lifestyle, metabolic health, and cardiovascular disease: a prospective UK Biobank study
    Yun, Jae-Seung
    Jung, Sang-Hyuk
    Shivakumar, Manu
    Xiao, Brenda
    Khera, Amit V.
    Won, Hong-Hee
    Kim, Dokyoon
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [4] Metabolic syndrome and subsequent risk of type 2 diabetes and cardiovascular disease in elderly women: Challenging the current definition
    Dragsbaek, Katrine
    Neergaard, Jesper S.
    Laursen, Janne M.
    Hansen, Henrik B.
    Christiansen, Claus
    Beck-Nielsen, Henning
    Karsdal, Morten A.
    Brix, Susanne
    Henriksen, Kim
    MEDICINE, 2016, 95 (36)
  • [5] Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients
    Mosenzon, Ofri
    Miller, Eden M.
    Warren, Mark L.
    POSTGRADUATE MEDICINE, 2020, 132 : 37 - 47
  • [6] Cost of healthcare utilization associated with incident cardiovascular and renal disease in individuals with type 2 diabetes: A multinational, observational study across 12 countries
    Norhammar, Anna
    Bodegard, Johan
    Eriksson, Jan W.
    Haller, Hermann
    Linssen, Gerard C. M.
    Banerjee, Amitava
    Karasik, Avraham
    Mamouris, Pavlos
    Tangri, Navdeep
    Taveira-Gomes, Tiago
    Maggioni, Aldo P.
    Botana, Manuel
    Thuresson, Marcus
    Okami, Suguru
    Yajima, Toshitaka
    Kadowaki, Takashi
    Birkeland, Kare, I
    DIABETES OBESITY & METABOLISM, 2022, 24 (07) : 1277 - 1287
  • [7] Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?
    Hanssen, Nordin M. J.
    Jandeleit-Dahm, Karin A. M.
    DIABETES & VASCULAR DISEASE RESEARCH, 2019, 16 (04) : 303 - 309
  • [8] Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
    Htay, Thwe
    Soe, Kyaw
    Lopez-Perez, Arianna
    Amy HoangAnh Doan
    Romagosa, Michael A.
    Aung, KoKo
    CURRENT CARDIOLOGY REPORTS, 2019, 21 (06)
  • [9] Cardiovascular Outcomes of New Medications for Type 2 Diabetes
    Trujillo, Jennifer M.
    Wettergreen, Sara A.
    Nuffer, Wesley A.
    Ellis, Samuel L.
    McDermott, Michael T.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 (12) : 749 - 758
  • [10] Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial
    Mahaffey, Kenneth W.
    Tuttle, Katherine R.
    Arici, Mustafa
    Baeres, Florian M. M.
    Bakris, George
    Charytan, David M.
    Cherney, David Z., I
    Chernin, Gil
    Correa-Rotter, Ricardo
    Gumprecht, Janusz
    Idorn, Thomas
    Pugliese, Giuseppe
    Rasmussen, Ida Kirstine Bull
    Rasmussen, Soren
    Rossing, Peter
    Sokareva, Ekaterina
    Mann, Johannes F. E.
    Perkovic, Vlado
    Pratley, Richard
    EUROPEAN HEART JOURNAL, 2024, : 1096 - 1108